Suppr超能文献

与医疗保险D部分队列中骨科医生减少阿片类药物处方相关的州医用大麻法律。

State Medical Cannabis Laws Associated With Reduction in Opioid Prescriptions by Orthopaedic Surgeons in Medicare Part D Cohort.

作者信息

Lopez Cesar D, Boddapati Venkat, Jobin Charles M, Hickernell Thomas R

机构信息

From the Department of Orthopedic Surgery, Columbia University Irving Medical Center, New York, NY.

出版信息

J Am Acad Orthop Surg. 2021 Feb 15;29(4):e188-e197. doi: 10.5435/JAAOS-D-19-00767.

Abstract

INTRODUCTION

Opioid prescriptions and abuse remain a significant national concern. Cannabinoids offer a potentially attractive nonopioid analgesic option for orthopaedic patients, and 32 US states have passed medical cannabis laws (MCLs), legalizing patient access to cannabinoids. We examine the association between implementation of state cannabis laws and prescribing patterns for opioids by orthopaedic surgeons in Medicare Part D patients between 2013 and 2017.

METHODS

Using the Medicare Part D Prescription Drug Event database, we measured annual aggregate daily doses of all opioid medications (excluding buprenorphine) prescribed by orthopaedic surgeons in each US state (and DC), in addition to total daily doses of opioid medications by generic name (hydrocodone, oxycodone, fentanyl, morphine, methadone, and "other opioids"). We used adjusted linear regression models to examine associations between state-specific cannabis regulations (state MCL, MCL type-dispensary or home cultivation, and recreational cannabis legalization) and annual total daily doses of opioid medications (all opioids and opioid types, separately).

RESULTS

State MCLs were associated with a statistically significant reduction in aggregate opioid prescribing of 144,000 daily doses (19.7% reduction) annually (95% confidence interval [CI], -0.535 to -0.024 million; P < 0.01). States with MCLs allowing access to in-state dispensaries had a statistically significant reduction in total opioid prescriptions of 96,000 daily doses (13.1%) annually (95% CI, -0.165 to -0.026 million; P < 0.01). Specifically, MCLs were associated with a statistically significant reduction of 72,000 daily doses of hydrocodone annually (95% CI, -0.164 to -0.019 million; P < 0.01). No significant association between recreational marijuana legalization and opioid prescribing was found.

CONCLUSION

Orthopaedic surgeons are among the highest prescribers of opioids, highlighting the importance of providing nonopioid analgesic alternatives in efforts to reduce opioid use in the patient cohort. This study is the first to examine the association between implementation of state cannabis laws and prescribing patterns for opioids by orthopaedic surgeons in Medicare Part D patients.

LEVEL OF EVIDENCE

Population-based ecological study.

摘要

引言

阿片类药物的处方和滥用仍是美国全国关注的重大问题。大麻素为骨科患者提供了一种潜在的、有吸引力的非阿片类镇痛选择,并且美国32个州已通过医用大麻法律(MCLs),使患者能够合法使用大麻素。我们研究了2013年至2017年期间各州大麻法律的实施与医疗保险D部分患者中骨科医生开具阿片类药物的处方模式之间的关联。

方法

利用医疗保险D部分处方药事件数据库,我们测量了美国每个州(及华盛顿特区)骨科医生开具的所有阿片类药物(不包括丁丙诺啡)的年度总日剂量,以及按通用名(氢可酮、羟考酮、芬太尼、吗啡、美沙酮和“其他阿片类药物”)分类的阿片类药物的每日总剂量。我们使用调整后的线性回归模型来研究各州特定的大麻法规(州MCL、MCL类型——药房配给或家庭种植,以及娱乐用大麻合法化)与阿片类药物的年度每日总剂量(分别为所有阿片类药物和阿片类药物类型)之间的关联。

结果

州MCLs与阿片类药物处方总量每年在统计学上显著减少144,000日剂量(减少19.7%)相关(95%置信区间[CI],-0.535至-0.024百万;P<0.01)。允许在本州药房获取大麻的MCLs州,阿片类药物处方总量每年在统计学上显著减少96,000日剂量(13.1%)(95%CI,-0.165至-0.026百万;P<0.01)。具体而言,MCLs与每年氢可酮日剂量在统计学上显著减少72,000相关(95%CI,-0.164至-0.019百万;P<0.01)。未发现娱乐用大麻合法化与阿片类药物处方之间存在显著关联。

结论

骨科医生是阿片类药物的高处方者之一,这凸显了在减少患者群体阿片类药物使用的努力中提供非阿片类镇痛替代方案的重要性。本研究首次探讨了各州大麻法律的实施与医疗保险D部分患者中骨科医生开具阿片类药物的处方模式之间的关联。

证据水平

基于人群的生态学研究。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验